KR20210094584A - Gdf15 유사체 및 체중을 감소시키고/시키거나 음식 섭취량을 감소시키는 데 사용하기 위한 방법 - Google Patents

Gdf15 유사체 및 체중을 감소시키고/시키거나 음식 섭취량을 감소시키는 데 사용하기 위한 방법 Download PDF

Info

Publication number
KR20210094584A
KR20210094584A KR1020217018694A KR20217018694A KR20210094584A KR 20210094584 A KR20210094584 A KR 20210094584A KR 1020217018694 A KR1020217018694 A KR 1020217018694A KR 20217018694 A KR20217018694 A KR 20217018694A KR 20210094584 A KR20210094584 A KR 20210094584A
Authority
KR
South Korea
Prior art keywords
dose
administered
study
fusion protein
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217018694A
Other languages
English (en)
Korean (ko)
Inventor
홀리 킴코
로버트 헤르만
로버트 헤르만
엘리사 팝브리니
엘리사 팝브리니
베드라나 스토자노빅-수슬릭
폴 로텐버그
송마오 정
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20210094584A publication Critical patent/KR20210094584A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020217018694A 2018-11-20 2019-11-19 Gdf15 유사체 및 체중을 감소시키고/시키거나 음식 섭취량을 감소시키는 데 사용하기 위한 방법 Pending KR20210094584A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769675P 2018-11-20 2018-11-20
US62/769,675 2018-11-20
PCT/IB2019/059945 WO2020104948A1 (en) 2018-11-20 2019-11-19 Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake

Publications (1)

Publication Number Publication Date
KR20210094584A true KR20210094584A (ko) 2021-07-29

Family

ID=70773869

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217018694A Pending KR20210094584A (ko) 2018-11-20 2019-11-19 Gdf15 유사체 및 체중을 감소시키고/시키거나 음식 섭취량을 감소시키는 데 사용하기 위한 방법

Country Status (15)

Country Link
US (1) US20220315633A1 (https=)
EP (1) EP3883960A4 (https=)
JP (2) JP2022513098A (https=)
KR (1) KR20210094584A (https=)
CN (2) CN113474363A (https=)
AU (2) AU2019383019A1 (https=)
BR (1) BR112021009225A2 (https=)
CA (1) CA3120236A1 (https=)
EA (1) EA202191424A1 (https=)
IL (1) IL283189A (https=)
JO (1) JOP20210111A1 (https=)
MX (1) MX2021005908A (https=)
PH (1) PH12021551119A1 (https=)
SG (1) SG11202104952PA (https=)
WO (1) WO2020104948A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9131966B2 (en) * 2013-03-11 2015-09-15 DePuy Synthes Products, Inc. Vertebral manipulation assembly
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
JP6946304B2 (ja) * 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
EA202191105A1 (ru) * 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение

Also Published As

Publication number Publication date
JOP20210111A1 (ar) 2021-05-19
CN121818901A (zh) 2026-04-10
BR112021009225A2 (pt) 2021-10-05
AU2019383019A1 (en) 2021-06-03
JP2022513098A (ja) 2022-02-07
EP3883960A4 (en) 2022-11-09
WO2020104948A1 (en) 2020-05-28
MX2021005908A (es) 2021-09-08
PH12021551119A1 (en) 2021-11-22
AU2025202337A1 (en) 2025-04-24
US20220315633A1 (en) 2022-10-06
JP2025081388A (ja) 2025-05-27
EA202191424A1 (ru) 2021-08-24
IL283189A (en) 2021-06-30
EP3883960A1 (en) 2021-09-29
SG11202104952PA (en) 2021-06-29
CA3120236A1 (en) 2020-05-28
CN113474363A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
TWI459962B (zh) 包含胰島素、菸鹼醯胺及胺基酸的製劑
JP5269945B2 (ja) インスリングラルギンの長時間作用型製剤
US12453726B2 (en) Methods of using factor B inhibitors
ES2733220T3 (es) Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento
KR102578030B1 (ko) 인슐린 글라진／릭시세나티드 고정비 제형
JP2019056013A (ja) ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療
AU2025202337A1 (en) GDF15 analogs and methods for use in decreasing body weight and/or reducing food intake
KR20250150148A (ko) 렙틴 수용체 작용제 항체를 사용한 치료 방법
AU2010328305B2 (en) BChE albumin fusions for the treatment of cocaine abuse
JP2021532761A (ja) 新規ニコチン分解酵素変異体
US20050197286A1 (en) Method for control of depression using c terminal growth hormone (gh) fragment
CA3072903A1 (en) Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
US12589141B2 (en) DNA vaccine capable of effectively treating and/or preventing type 1 diabetes and use thereof
EA009988B1 (ru) Применение человеческого гормона роста при множественной системной атрофии
JP2019525931A (ja) ヒト成長ホルモンアナログによる成人成長ホルモン欠乏症の処置
Moretz Orphan Drug Evaluation: Myalept®(metreleptin) subcutaneous injection
TW202135852A (zh) 用於治療肥胖症之使用升糖素和glp-1共促效劑之組合療法
TW202140061A (zh) 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
Class et al. Patent application title: BChE ALBUMIN FUSIONS FOR THE TREATMENT OF COCAINE ABUSE Inventors: Liora Sklair-Tavron (Zichron Yaakov, IL) Moti Rosenstock (Menashe, IL) Liron Shemesh-Darvish (Ramat-Gan, IL) Hussein Hallak (Jerusalem, IL) Victor Piryatinsky (Netanya, IL) Viktor Roschke (Bethesda, MD, US) Viktor Roschke (Bethesda, MD, US) David Lafleur (Washington, DC, US) David Lafleur (Washington, DC, US) Assignees: Teva Pharmaceutical Industries Ltd.
AU2003223252A1 (en) Method for control of depression using c terminal growth hormone (gh) fragment
KR20060079183A (ko) 다발성 뇌신경계 위축증에서의 인간 성장 호르몬의 용도
HK1121039A (en) Methods for treating b-cell malignancies using taci-ig fusion molecule

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000